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ABSTRACT

Lysophosphatidic acid (LPA) is a potent bioactive lipid component of oxidized
low density lipoproteins (oxLDL). High concentrations of LPA have been detected in
human atherosclerotic plaques. Our data has shown that LPA highly induces smooth
muscle cell (SMC) migration. Cyr61, a matricellular protein, which also accumulates
in human atherosclerotic plaques, has been implicated in the injury-induced
neointimal formation. Smooth muscle cell migration is a key event in the
development of atherosclerosis, and it contributes to the progressive growth of
atherosclerotic lesions. Data generated by this study demonstrate that LPA markedly
induces Cyr61 expression in mouse aortic smooth muscle cells (MASMC). We
hypothesized that LPA-induced matricellular Cyr61 mediates LPA-induced MASMC
migration. To date, little is known about the relationship between LPA and Cyr61 in
smooth muscle cells; the signaling pathway leading to LPA-induced Cyr61 is
unknown. Furthermore, whether Cyr61 contributes to LPA-induced cell migration is
unrevealed. Our study demonstrates that LPA, by binding to LPA1 receptor, activates
the intracellular signaling pathway leading to the activation of PKCwhich in turn
contributes to the increased expression of Cyr61 in MASMCs. Interestingly, we found
that after LPA-induced Cyr61 mRNA has been translated into its protein
intracellularly, the de novo synthesized proteins promptly accumulate in the Golgi
apparatus and then translocalize to the extracellular matrix. Importantly, our data
reveal a novel LPA/Cyr61 pathway in controlling MASMC migration. Understanding
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the mechanism underlying LPA induction of Cyr61 provides new insight into
pathogenesis of atherosclerosis.
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INTRODUCTION

Cardiovascular diseases are the No.1 cause of death in the United States.
Atherosclerosis is a major component of cardiovascular disease, the primary cause of
heart disease and stroke. It is the underlying cause of about 50% of all deaths in
westernized societies. Over the past years, the mechanism of atherosclerosis has been
more understood. Atherosclerosis is a chronic inflammatory condition, which causes a
progressive disease characterized by the accumulation of lipids, cells and fibrous
elements in the large arteries [1].

NORMAL ARTERIES
The basic components of blood vessels are cells, mostly endothelial cells (ECs)
and smooth muscle cells (SMCs), and extracellular matrix, which includes collagen,
elastin and glycosaminoglycans [2].
There are three concentric layers (intima, media, and adventitia) in the arterial
walls. The intima consists of a single layer of ECs with little underlying
subendothelial connective tissue and is bordered by internal elastic lamina. The
endothelial cells form a firm barrier between the vessel lumen and the stroma of the
arterial wall. Research has revealed that endothelial cells regulate a wide set of
functions in the arterial wall, including vascular tone and structure, and they exhibit
anticoagulant, antiplatelet, and fibrinolytic properties [3].
The most prominent constituent of the media layer is smooth muscle cells. These
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cells are held together by an extracellular matrix which consists mostly of elastic
fibers and collagen. These cells may also be attached together by junctional
complexes. The smooth muscle cell is the main contributor to production of the
extracellular matrix [4]. It is well known that the vascular smooth muscle has the
function of controlling vascular tone through contraction or relaxation. The vascular
smooth muscle has also been shown to be involved in the regulation of cell growth,
death, and migration, as well as matrix modulation and inflammation. These functions
of vascular smooth muscle play important roles in beneficial physiological vascular
functions, such as vascular remodeling, and also in pathological disorders, such as
atherosclerosis, restenosis, transplant vasculopathy, and other vascular diseases [5].
The outer limit of the media is defined by the external lamina. The outermost layer
of the artery is the adventitia, consisting of the connective tissue with nerve fibers and
the vasa vasorum [6]. The adventitia is thought to be a major source of vasoactive
factors and a pivotal participant in vascular remodeling. Over the past years the
researchers noted that the changes occurring in the adventitia may be a signal of
impending vascular disease, with typical hypercellularity, increased connective tissue
production, and clear signs of inflammation [7].

ATHROSCLEROSIS
Atherosclerosis is a progressive disease caused by the accumulation of lipids and
fibrous elements in the large arteries. (1) The intimal lesions are called atheromas or
fibrofatty plaques, which protrude into and obstruct vascular lumina, weaken the
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underlying media, and finally cause serious complications. Atherosclerosis mostly
affects elastic arteries and large and medium muscular arteries. As a result, acutely or
chronically diminished or stopped arterial perfusion leads to lots of severe
consequences, including mesenteric occlusion, chronic ischemic heart disease, sudden
cardic death and encephalopathy.
Due to the overwhelming clinical importance of atherosclerosis, over the past
decades scientists have put enormous efforts into discovering the mechanism behind
the diseases. The current concept, called the response to injury hypothesis, considers
that atherosclerosis is a chronic inflammatory response of the arterial wall initiated by
injury to the endothelium. Hyperlipidemia, and other risk factors, cause chronic
endothelia injury, which yields increased permeability, leukocyte adhesion and
thrombotic potential. As a result, lipoproteins, mostly Low-density Lipoprotein (LDL),
accumulate in the subendothlial matrix. Meanwhile, blood monocytes adhere to the
endothelium and migrate into the intima and then are transformed into macrophages.
Under the induction of free redicals generated by macrophages or EC,
accumulated LDL is modified through oxidation, proteolysis, lipolysis and
aggregation [2][8]. Distinct from native LDL, oxidized LDL can be ingested by
macrophages through the scavenger receptor, leading to the formation of the foam
cells. It can also stimulate the overlying ECs to produce a number of proinflammatory
molecules, including adhesion molecules and growth factors. In the lumen, platelets
adhere to the endothelial cells and become activated. After being activated, platelets
release numerous imflammatory factors, and they, together with other factors released
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by other cells cause the smooth muscle cells to migrate from the media into the intima
Finally, SMC proliferation and the extracellular matrix that SMCs deposit in the
intima convert a fatty steak into a mature firbrofatty atheroma, leading to the
progressive growth of atherosclerosis lesions [2]. Most importantly, in the
development of atherosclerosis SMC migration and proliferation are key events .

RISK FACTORS:
Over the past years, epidemiological studies have revealed numerous risk factors
for atherosclerosis. The well-established familial predisposition to causes of
atherosclerosis is polygenic. Age, along with other factors, including hyperlipidemia,
smoking, diabetes mellitus, homocystinemia, contribute to the development of the
atherosclerosis [2]. Among the risk factors, low density lipoprotein is one of the most
important risk factors. And the most pathogenic form of LDL is the oxidized LDL.

LYSOPHOPHATIDIC ACID (LPA):
Oxidized low density lipoprotein (LDL) is an important contributor in the
pathogenesis of atherosclerosis and its thrombotic complications, such as stroke and
myocardial infarction. It has been found that lysophosphatidic acid (LPA) is formed
during mild oxidation of LDL and is the active compound in mildly oxidized LDL and
minimally modified LDL. LPA also initiates platelet activation and stimulates
endothelial cell stress-fiber and gap formation. Furthermore, LPA is the primary
platelet-activating lipid of atherosclerotic plaques, and the amount of LPA within the
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human carotid atherosclerotic lesion is highest in the lipid-rich core, which is the
region most thrombogenic and most prone to rupture [9].
LPA, a potent bioactive lipid, elicits a variety of cellular responses in various cell
types including proliferation, migration, prevention of apoptosis, cytokine and
chemokine secretion, platelet aggregation, smooth muscle contraction, and neurite
retraction. LPA has multiple effects on vessel wall cells and blood platelets. Our group
has reported that LPA induces the expression of transcription factor, Early Response
Gene-1 (EGR-1) and coagulation initiator, tissue factor (TF) in aortic smooth muscle
cells, and promotes interleukin 6 secretion from aortic smooth muscle cells. These
results imply that LPA might play a role in vascular inflammation and thrombosis
[10][11][44]. Our recent data and previous studies demonstrate that LPA induces
smooth muscle cell migration and proliferation. Given the fact that smooth muscle
cell migration is an important future of atherogenesis, it is of great clinic importance
to understand the molecular mechanism of LPA induction of smooth muscle cell
migration.

LPA RECEPTORS:
LPA is an extracellular ligand for a family of G protein-coupled receptors.
Through binding to the LPA receptors, LPA activates intracellular signaling pathways,
which have been shown to be involved in many essential cellular processes [12]. At
least 5 LPA receptors have been identified. They are LPA1–5, which are widely
expressed in various cells and mammalian organ systems, such as cardiovascular,
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nervous and reproductive systems [13].
LPA1, also called EDG2, was the first identified LPA receptor [14]. It is highly
expressed in many organ tissues including brain, heart, lung, thymus, testis, stomach,
small intestine, spleen, and skeletal muscle in adult mice [15] and has also been
detected in numerous human tissues such as brain, heart, placenta, spleen, kidney,
colon, small intestine, prostate, testis, ovary, pancreas, thymus, and skeletal muscle
[16]. It is reported that LPA1 is involved in cell proliferation, serum-response element
(SRE) activation, MAPK activation, PLC/PKC activation, Akt activation, and Rho
activation through three types of G proteins: Gi/o, Gq, and G12/13 [17] [18].
LPA2, also called EDG4, was the second LPA receptor identified by sequence
homology searches using LPA1 [16] [19]. It shows gene express in embryonic brain,
testis, kidney, lung, thymus, spleen, and stomach in mice [15]. LPA2 has also been
detected in human tissues including testis, pancreas, prostate, thymus, spleen, and
peripheral blood leukocytes [16]. Like LPA1, LPA2 signaling is also via three G
proteins: Gi/o, Gq, and G12/13 [19] [20]. Within MEFs, LPA2 has been shown to have
redundant functions in mediating PLC activation, proliferation, JNK activation, Akt
activation, and stress fiber formation [21].
LPA3, also called EDG7, was identified by degenerate polymerase chain reaction
(PCR)-based cloning and homology searches [22][23]. LPA3 is found in kidney, lung,
testis, small intestine, heart, thymus, brain, oviduct, placenta, and uterus in adult mice
[15]. It is also detected in heart, pancreas, prostate, testis, lung, ovary, and brain in
humans [22][23]. LPA3 couples to Gi/o and Aug protein, but unlike LPA1 and LPA2, it
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does not couple to G12/13 [18]. LPA3 signaling induces PLC activation,
Ca2+mobilization, AC inhibition/activation, and MAPK activation [18][22][23].
LPA4, also called p2y9/GPR23, was identified during a “de-orphaning” project of
G protein-coupled receptors. It is found in human ovary, kidney, skeletal muscle [24]
and has also been detected in brain, heart, lung, thymus, kidney, skeletal muscle,
ovary, uterus, and placenta in adult mice. LPA4 signaling couples with Gq/11 and Gs
proteins [25].
LPA5 also called GPR92 was a GPCR closely related to LPA4 [26], sharing at
most 35% sequence identity with LPA4 and lower identities compared with LPA1–3. It
is highly expressed in small intestine, and is also detected in spleen and stomach of
adult mice. It has been demonstrated that LPA5-mediated signaling is relevant to
normal function, most likely in concert with previously identified receptors [27].

CYSTEINE-RICH PROTEIN 61:
Although the extracellular matrix was considered a benign scaffold for arranging
cells within connective tissues for many years, it is now being redefined as a dynamic,
mobile, and flexible regulator of cellular behaviour [28]. The ECM can regulate the
bioavailability and activity of growth factors, chemokines, cytokines and extracellular
enzymes. Moreover, ECM proteins can also directly interact with cell surface
receptors, triggering the activation of signal transduction cascades, and regulating
diverse cellular functions [29].
The CCN proteins are an important family of matricellular regulatory factors
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involved in internal and external cell signaling, in angiogenesis, chondro-genesis, and
osteogenesis, and they probably participate in the control of cell proliferation and
differentiation [30].
Cysteine-rich 61 (Cyr61, CCN1) is a Error! Reference source not found. that is
encoded by the Cyr61 gene [31]. As a member of the CCN protein family,
CCN1/Cyr61 plays important roles in cell proliferation, adhesion, differentiation,
angiogenesis and extracellular matrix production. Moreover, CCN1/Cyr61 also has
many potential functions in tumorigenesis, development, embryo implantation, as
well as formation of endometriotic lesions. Various agents, including cytokines,
growth factors, steroid hormones, and some drugs, regulate expression of
CCN1/Cyr61 through several signaling transduction pathways. As a result,
CCN1/Cyr61 is not only able to regulate the growth of epithelial cells and fibroblasts,
but also to induce or suppress apoptosis in a specific cell type [32].
Cyr61 regulates SMC proliferation, adhesion, migration, differentiation,
apoptosis, extracellular matrix production, which are important steps in the initiation
and progression of atherosclerosis, therefore Cyr61 could be one important regulator
in the process of atherosclerosis.
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MATERIAL AND METHODS

MATERIALS:
LPA (1-Acyl-2-hydroxy-sn-glycerol-3-phosphate) in this study was purchased
from Avanti Polar Lipids, Inc; transient chambers (6.5 mm diameter, with 8.0 μm pore
size polycarbonate membranes) were from Corning Costar Corp; and phosphate buffer,
Harris hematoxylin solution, and eosin Y solution were from Sigma; PD98059 (PD),
SB203580 (SB), U0126 (U0), GF109203X (GF), GO6976, GO6983, SP600125 (SP),
Wortmannin, LY294002 (LY) and Rottlerin were from Enzo Life Science. Resveratrol
was from EMD. Antibody against actin was from Sigma; Antibodies against Mouse
Cyr61 was from R&D System; Antibodies against adaptin was from BD Transduction
Laboratories; Antibodies against Egr-1, p-JNK, p-AKT, p-ERK, p-PKD, p-PKC,
p-PKC, p-P38, p-PKC, p-PKC p-PKC, PKD1, PKD2, and MEK were from Cell
signaling; Rhodamine Red-X-conjugated AffiniPure goat anti-mouse IgG was from
Jackson ImmunoResearch Laboratories. Goat anti-sheep IgG Alexa Fluor 488 was
from Invitrogen; SelectFX Nuclear Labeling Kit and SlowFade Gold antifade reagent
were from Invitrogen; mouse PKC siRNA, mouse PKC siRNA, mouse PKD1
siRNA and mouse PKD2 siRNA were from Qiagen; VECTASTAIN ABC kit and
peroxidase substrate kit DAB were from Vector Laboratories, INC. Hybond-N
membranes were from GE Healthecare. Trizol reagent was from Invitrogen. GoTaq
Flexl DNA Polymerase and Reverse Transcription system were from Promega.
RNeasy Mini Kit was from Qiagen. Recombinant Cyr61 protein was from Abcam.
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Fast Optical 96-Well Reaction Plaste with Barcode, Taqman Gene Expression Master
MixReal time, Mouse LPA1-5 receptors primers for Real time PCR reagents were from
Applied Biosystem.

CELL CULTURE:
Mouse aorta smooth muscle cells (MASMCs) were prepared from explants of
excised aortas of mice and rats as described previously [33]. Cells between 10 and 20
were used in these studies. Cells were cultured in Dulbecco's modified Eagle's
medium containing 10% fetal bovine serum and 1% glutamine. For Western blot
assays, cells were starved for 48 hours prior to addition of LPA or other reagents. For
cell migration assay, prior to the cell migration assay, cells were starved for 24 hours.

SMOOTH MUSCLE CELLS WESTERN BLOT ANALYSIS
Mouse aortic SMCs (MASMCs) were rinsed with cold PBS and then lysed in cell
lysis buffer (50 mM Tris–HCl, pH 6.8, 8 M urea, 5%-mercaptoethanol, 2% SDS, and
protease inhibitors) with sonication for 30 s on ice. After addition of 4X SDS sample
buffer and incubation at 65 °C for 20 minutes, samples were subjected to 10% SDS
polyacrylamide gel electrophoresis and were transferred to a polyvinylidene fluoride
membrane (Immobilon-P, Millipore). The membranes were then probed with the
specific first antibodies, after being washed in TBST 4 times (5 minutes for each), the
membranes were incubated in specific second antibodies, which depended on the
source of the first antibody used, and finally the bands were visualized by ECL Plus
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(GE Healthcare) as described previously [11].

CELL MIGRATION ASSAY
Cell migration was performed using transwell migration plates purchased from
Corning. Mouse smooth muscle cells were trypsinized and plated onto transwell
plates for migration assays. A volume of 200 μl media containing 2×105 cells was
added to the upper chamber. Cells were allowed to migrate through filters (8 μm pore
size), which had been precoated on both sides with gelatin, in the presence of either
medium (600 μl) alone or medium with LPA at designated concentrations in the lower
chamber. Cell migration was carried out at 37 °C in 5% CO2 for 6 h. Cells remaining
on the upper surface of the filter were carefully removed by mechanical scraping. The
upper chambers were rinsed with PBS, and the cells were fixed with methanol and
then stained with Harris hematoxylin and eosinY. The number of cells that had
migrated to the lower surface of the filter was counted in 4 random objective fields
(200×magnification) using a Nikon Eclipse E600 microscope.

IMMUNOFLUORESCENCE
MASMCs grown in 6-well chamber coverglass slides were fixed in 4% ice cold
paraformaldehyde solution for 30 minutes, permeablized with or without 0.3% triton
X-100 in PBS for 5 minutes at room temperature, blocked with 5% goat serum
(Sigma) plus 0.1% Tween-20 in PBS for 1 hour, and then incubated with Cyr61
antibody and adaptin in 1/100 dilution overnight at 4 °C. After being washed with
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mild shaking with PBS 3 times (5 minutes for each), the cells were incubated with the
secondary antibody, goat anti-sheep IgG Alexa Fluor 488 or Rhodamine
Red-X-conjugated AffiniPure goat anti-mouse IgG for 2 hours at room temperature.
Then the cells were washed with PBS 4 times (5 minutes for each) at room
temperature, and then incubated with DAPI for 2 minutes and washed with PBS 3
times (5 minutes for each) at room temperature. Subsequently, the coverslips were
mounted on slides with permanent aqueous mounting medium (Biogenex), and the
labeled cells were analyzed by fluorescence microscopy with a Nikon Eclipse E600
microscope.

IMMUNOPRECIPITATION
After being stimulated with 5 M LPA for 3, 5, 12, or 24 hours, MASMCs were
harvested

and

conditioned

media

was

collected.

Secreted

Cyr61

was

immunoprecipitated from conditioned media using the sheep anti-mouse Cyr61
antibody from R&D System. To detect intracellular Cyr61 protein with the
immunoprecipitation, cells were homogenized with buffer A (20 mM HEPES, PH7.4,
50 mM KCl, 2 mM EDTA, protease inhibitor cocktail from ROCHE) by passing
through 20-gauge needles for 15 times after freezing and thawing 5 times in liquid
nitrogen and at 37 °C water bath. The homogenized samples were then centrifuged at
800 x g for 10 minutes to separate the post nuclear supernatant (PNS) from the
unbroken cells and nuclei. PNS was further subjected to centrifugation at 20,000 x g
for 1 hour and the pellet was solubilized in buffer B (50 mM PIPES, pH7.0, 150 mM
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KCl, 5 mM MgCl2, 5 mM CaCl2, and protease inhibitor cocktail with 1% CHAPSO)
for 1 hour at 4 °C, and then centrifuged again at 20,000 x g for 30 minutes. After the
supernatant was incubated with the Cyr61 antibody and protease inhibitor cocktail for
3 hours with rotation at 4 °C, Protein A sepharose beads were added and incubated
overnight with rotation. The immunocomplex was washed with Buffer B four times
and then lysed with PARP buffer, the samples were subjected to 10% SDS-PAGE gel.

ADENOVIRAL INFECTION OF MASMCs
Adenoviruses encoding mouse PKC subtype was constructed as previously
described [34]. MASMCs were infected for 24 h with either wild type or dominant
negative PKC adenovirus, then starved for 48 hours followed by treatment either
with or without LPA.

SMALL INTERFERING RNA (siRNA) TRANSFECTION:
MASMCs were cultured in RPMI 1640 medium with 10% fetal bovine serum.
Signal Silence Control siRNA (non-silencing siRNA, 40 nM), Mouse PKC siRNA
(40 nM), Mouse PKC siRNA (40 nM), Mouse PKD1 siRNA (40 nM), mouse PKD2
siRNA (40 nM) were transfected according to the manufacturer's instructions (Cell
Signaling Technology). The Signal Silence Control siRNA was used as a negative
control. Forty-eight hours after transfection, the cells were trypsinized and transfected
with siRNA again. After forty-eight hours the cells were starved for 48 h followed by
treatment either with or without LPA.
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PREPARATION OF CELL LYSATES AND ECM
MASMCs were grown in 60 mm dishes and treated as described before. After
removal of the culture medium and rinsed with PBS, cells were detached from the
dish by incubation with 1 mM EDTA. The dishes were then rinsed twice with EDTA
to remove remaining cells. Cellular fractions were lysed with PARP buffer, sonicated
on ice, added with 4x loading buffer, and incubated in 65 °C for 15 min prior to
analysis. Extracellular material remaining on the dishes after removal of the cellular
components was extracted by scraping at 90°C in 1 x Laemmli sample buffer (I x = 60
mM Tris -HCI, pH 6.8, 2% SDS, 5 % fl-mercaptoethanol, 5% glycerol) . These
fractions were designated ECM.

NORTHERN BLOTTING ANALYSIS FOR DETECTION OF
MASMCS CYR61 mRNA:
Total cellular mRNA was isolated according to the manufacturer’s instruction.
Total

RNA

(6-8

formaldehyde/agarose

g)
gels

was
and

subjected
was

Hybridization was carried out using

32

to

blotted

denaturing
onto

electrophoresis

Hybond-N

in

membranes.

p-labeled Cyr61 cDNA probes. A 0.7 kb

fragment of mouse Cyr61 cDNA was used to detect Cyr61 mRNA. 18S and 28S
ribosomal RNA was used as an internal control.

RT-PCR ASSAY:
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Expression of mRNA was evaluated by RT-PCR. Total RNA was isolated from
MASMCs and mouse tissues using a Trizol Reagent. The first strand of cDNA was
reverse transcribed using the reverse transcription system. The cDNA products were
amplified using GoTaq Flexl DNA Polymerase. The amplification conditions were as
follows: 5min at 95 °C; 27 to 33 cycles of 30 s at 95 °C, 30 s at 55 °C, and 1 min at
72 °C; this was followed by a final extension for 10 min at 72 °C. The primers were
used as follows: LPA1, 5′-AGC TGC CTC TAC TTC CAG C-3′(forward) and 5′-TTG
CTG TGA ACT CCA GCC AG-3′ (reverse); LPA2, 5′-ATG GGC CAG TGC TAC
TAC AAC G-3′ (forward) and 5′ AGG GTG GAG TCC ATC AGT G-3′ (reverse);
LPA3, 5′-GAC AAG CGC ATG GAC TTT-3′ (forward); 5′-CAT GTC CTC GTC CTT
GTA CG-3′ (reverse)); LPA4, 5′-GTT GTA TTC ATC CTG GGT CT-3′ (forward);
5′-AGC GAC TCC ATC CTT ATA TG-3′ (reverse); LPA4, 5′-TGC TCT GAC CTT
GTT GTT CC-3′ (forward); 5′-AGC AAC CCA TAT ACA GCC AGC G-3′ (reverse)).
The PCR products were analyzed by electrophoresis on a 1.0% agarose gel.

STATISTICS:
Results are means ±SE. Comparisons between multiple groups were performed
using one-way ANOVA with post-hoc t-tests. Single comparisons were made using
two-tailed, unpaired Student's t-tests. A p value of 0.05 was considered to be
statistically significant.
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RESULTS
1. Cyr61 is markedly induced by LPA in MASMCs.

1.1 LPA markedly induces Cyr61 protein expression:
When MASMCs were stimulated with various concentrations of LPA after the
cells were starved for 48 hours, Cyr61 protein expression increased in response to
LPA stimulation in a concentration dependent manner with the maximal induction in
25-200 M (Figure 1). We also observed that LPA induction of Cyr61 protein was
transient, it increased from 30 minutes and peaked at 3 hours, then declined
dramatically after 3 to 6 hours (Figure 2). Our data reveal for the first time that LPA
induces Cyr61 expression in SMCs.

1.2 Induction of Cyr61 mRNA expression by LPA:
To determine whether LPA induction of Cyr61 protein expression is due to the
accumulation of Cyr61 mRNA, we examined the effect of LPA on Cyr61 mRNA
levels. We observed that LPA significantly increased Cyr61 mRNA accumulation in
quiescent MASMCs. The induction is also transient. The induction peak time is at
around 1 hour, and declined rapidly after 3 hours (Figure 3).
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Figure 1. Induction of Cyr61 protein in response to LPA in MASMC. LPA was added to
quiescent MASMCs at the concentrations indicated above each lane for 3 hours. Cyr61 protein
level was determined by western blotting with 10% SDS PAGE gel. Actin was used as the loading
control.

Figure 2. Time course of LPA induction of Cyr61 protein in MASMCs. 5 M LPA was added
to quiescent MASMCs for various times indicated. Cyr61 protein level was determined by western
blotting with 10% SDS PAGE gel. Actin was used as the loading control.
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Figure 3. Time course of LPA induction of Cyr61 mRNA in MASMCs. 5 M LPA was added
to quiescent MASMCs for various times indicated. Total mRNA was isolated, and Cyr61 mRNA
levels were determined by Northern blot analysis. A mouse Cyr61 cDNA fragment was used as a
probe. 18S rRNA was visualized by ethidium bromide staining.

- 18 -

1.3 LPA receptor expression in MASMCs, mouse aorta and carotid
arteries.
To determine the expression levels of LPA1-5 receptors in MASMCs, mouse aorta
and carotid arteries, total mRNA was extracted and RT-PCR was performed. We
observed that the expression levels of each type of LPA receptors in these cells and
tissues were similar, mainly because the major component of mouse aorta and carotid
arteries is the smooth muscle cells. As shown in figure 4, receptors LPA1, LPA2 and
LPA4 were highly expressed, LPA3 was expressed at a very low level and there is no
LPA5 receptor expressed in these cells and tissues.

1.4 The expression of LPA1-5 receptors in WT, LPA1-/-, LPA2-/- and
LPA3-/- MASMCs.
The above data showed LPA receptor expression in WT MASMCs, but it is
still unclear whether up-regulation or down-regulation of the other LPA receptor
genes occurred when certain LPA receptors were knockout. We have received LPA1
+/- mice from Dr. Jerold Chun, The Scripps Research Institute and successfully
established LPA1-/- and LPA2-/- mice and isolated smooth muscles cells from these
knockout mice. It was reported that LPA3 receptor was dramatically upregulated in
LPA1 knockout (KO) MASMCs [35], however, it was also reported that in LPA1-/adult brain, the change in transcript levels of LPA2 and LPA3 gene can not be
observed [36]. To determine whether LPA3 receptor was upregulated in LPA1-/- or
LPA2-/- MASMCs, we extracted total mRNA from each cell type and performed real
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time PCR. As shown in figure 5, there was no significant difference in the expression
levels of LPA3 in the LPA1 or LPA2 knockout cells compared to wild type, indicating
that there is no compensation of LPA3 in LPA1 or LPA2 knockout cells. Our Northern
blot data and Western blot data confirm this conclusion, as shown in figure 6, there is
no obvious changes in expression levels of LPA3 in LPA1-2 knockout MASMCs. We
next determined whether LPA stimulates LPA3 gene expression in WT and LPA1-/MASMCs. As shown in figure 7, the expression of LPA3 was not changed after LPA
stimulation, all of the above data strongly supported that LPA3 was not upregulated in
LPA1-/-, LPA2-/- MASMCs, and LPA stimulation has no effect on LPA3 receptor
expression, either.
We also examined whether expression levels of LPA1.2.4.5 receptors were
upregulated in LPA1-/-, LPA2-/-, LPA3-/- MASMCs. As shown in Figure 5, 6, 8 and 9,
there was no compensation phenomenon was observed in any of the LPA receptors in
LPA receptor knockout SMCs.

1.5 LPA receptor LPA1, but not PPAR, mediates LPA-induced Cyr61
protein expression.
To explore the intracellular pathways through which LPA exerts its functions, we
first evaluated the involvement of LPA receptors. Since LPA1, LPA2 and LPA4 are
predominantly expressed in MASMCs, we examined which LPA receptor mediated
LPA-induced Cyr61 protein expression. We stimulated quiescent wild-type LPA1-/and LPA2-/- MASMCs with LPA for 3 hours, and Cyr61 expression was detected by
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Western blot analysis. We observed that genetic depletion of LPA1 nearly completely
shut down LPA-induced Cyr61 protein expression; however, genetic depletion of
LPA2 has no effect on LPA induction of Cyr61 expression, indicating that LPA1
mediates Cyr 61 expression (Figure 11). To examine whether genetic depletion of
LPA receptors affect other stimulus-initiated signaling pathway, we determined the
influence of LPA1-/- and LPA2-/- on the EGF signaling pathway. Quiescent wild-type,
LPA1-/- or LPA2-/- MASMCs were stimulated with 100 ng/ml EGF for 5 minutes and
the phosphorylation of MAPKs was detected by Western blot analysis, the results
showed genetic depletion of LPA1 and LPA2 receptors had no effect on EGF-induced
phosphorylation of MAPKs (Figure 12). Besides LPA-specific plasma membrane
receptors, nuclear receptor PPAR-

has also been reported to work as an intracellular

receptor and to transmit the LPA signal to downstream molecules [37]. To examine
whether PPAR-

has a role in LPA-induced Cyr61 protein expression in MASMCs,

we determined the effect of the PPAR-

antagonist GW-9662 on LPA-induced Cyr61

protein expression. We observed that pretreatment of MASMCs with various
concentrations of GW-9662 (0.1–10 µM) for 45 min had no effect on the expression
levels of Cyr61 induced by LPA (Figure 10). The range of the concentrations used is
based on the information reported previously that 1 µM of GW-9662 efficiently
blocks PPARPPAR-

activation in vascular SMCs [38]. Our results indicate that the

pathway is not involved in the LPA induction of Cyr61 protein expression.
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Figure 4. R-T PCR results, LPA1-5 receptor expression in MASMCs, mouse aortas and
carotid arteries. Total mRNA from MASMC, mouse aorta and carotid arteries was extracted with
trizol reagent. After reverse transcritption, cDNA was used to perform RCR analysis with Mouse
LPA1-5 primers.
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Figure. 5. Real time PCR data, LPA1-5 receptor expression in MASMCs. Total mRNA from
MASMCs was extracted with RNeasy mini kit. After reverse transcription, cDNA was used to
perform Real time RCR analysis with Mouse LPA1-5 primers.
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Figure 6. A. Western blot analysis showing LPA3 receptor expression in WT, LPA1-/-, LPA2-/and LPA3-/- MASMCs. The tissue samples from mouse lung were used as a positive control, Erk
has been used as a loading control. B. Northern blot analysis showing LPA3 receptor expression in
WT, LPA1-/-,LPA2-/- and LPA3-/- MASMCs. Tissue samples from mouse lung were used as a
positive control, 28S and 18S rRNA were visualized by ethidium bromide staining. C. Total
mRNA of MASMCs, mouse aorta and carotid arteries was extracted with trizol reagent. After
reverse transcritption, cDNA was used as template DNA, which was amplified 30 cycles with
mouse LPA1-5 primer pairs. Tissue samples from mouse lung were used as positive controls.
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Figure 7. Northern blot analysis data: LPA3 expression levels in WT, LPA1-/-MASMCs after
stimulation with LPA. WT and LPA1-/-MASMCs were stimulated with LPA for the time periods
indicated above, the samples from mouse lung has been used as a positive control, 28S and 18S
rRNA were visualized by ethidium bromide staining.

Figure 8. Northern blot analysis, the expression of LPA1, LPA2, LPA4 and LPA5 in WT,
LPA1-/-, LPA2-/- and LPA3-/- MASMCs. The tissue from mouse lung was used as a positive
control for LPA1.2, 28S and 18S rRNA were visualized by ethidium bromide staining.
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Figure 9. A diagram showing the relative expression levels of LPA1.2.3.4.5 in WT, LPA1-/--,
LPA2-/- and LPA3-/- MASMCs.
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Figure 10. GW9662 has no effect on LPA-induced Cyr61 protein expression. Quiescent
MASMCs were pretreated with GW9662 at the concentrations indicated above for 45 minutes,
then 5 M LPA was added for 3 hours. Cyr61 protein level was determined by Western blotting
with 10% SDS-PAGE gel. Actin was used as the loading control.

Figure 11. LPA1, but not LPA2 mediates LPA-induced Cyr61 protein expression. 5 M LPA
was added to quiescent wild-type, LPA1-/- and LPA2-/- MASMCs for 3 hours, Cyr61 protein level
was determined by Western blotting with 10% SDS-PAGE gel. Actin was used as the loading
control.
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Figure 12. LPA receptors do not mediate EGF-induced signaling pathway. 100 ng/ml EGF
was added to quiescent wild-type, LPA1-/- and LPA2-/- MASMCs for 5 minutes, p-ERK, p-MEK,
and p-P38 were determined by Western blotting with 10% SDS-PAGE gel. The expression of ERK,
MEK and p38 were used as loading controls.
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1.4 MAPKs are not involved in LPA-induced Cyr61 expression.
Mitogen-activated protein kinases (MAPKS) are serine/threonine-specific protein
kinases, which respond to extracellular stimuli and regulate numerous cellular
activities, such as gene expression, cell differentiation and proliferation. MAPKS
have several subfamilies, such as extracellular signal-regulated kinases (ERKs), p38,
c-Jun N-terminal kinases (JNKs). Our data showed that LPA significantly induced the
phosphorylation of ERK, P38 and JNK in a time dependent manner (Figure 13), these
results prompted us to determine whether LPA-induced MAPKs play roles in LPA
induced Cyr61 protein production. MASMCs were pretreated with different
concentration of ERK inhibitors U0126 and PD98059 for 45 minutes, then 5 M LPA
was applied to every dish and stayed for 3 hours. The cell lysates were analyzed by
10% Tris/Glycine SDS-PAGE gel followed by Western blotting with anti-mouse
Cyr61 and p-ERK antibody. As shown in Figures 14 and 15, treatment with these
inhibitors didn't block LPA-induced Cyr61 protein expression, indicating that ERK is
not involved in LPA induction of Cyr61 protein. Using the same strategy, we
examined the effects of SB203580, a specific p38 inhibitor and SP600125, a specific
JNK inhibitor on LPA induction of Cyr61 protein expression, as shown in figure 16
and figure 17, none of those inhibitors had any effect on LPA-induced Cyr61
expression. This result excludes the possibility that p38 or JNKs plays a role in
LPA-induced Cyr61 expression.
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Figure 13. LPA induces the activation of MAPKs, Akt, and PKD in MASMC. 5 M LPA was
added to quiescent MASMC. At the time points indicated above, cells were lysed. The
phosphorylation of MAPKs, AKT and PKD was determined by Western blotting with 10% SDS
PAGE gel. The expression of MEK and actin was used as the loading control.
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Figure 14. U0126 doesn't block LPA-induced Cyr61 protein expression. Quiescent MASMCs
were pretreated with U0126 at the concentrations indicated above for 45 minutes, then 5 M LPA
was added and stayed in the medium for 3 hours. Cyr61 protein level was determined by Western
blotting with 10% SDS-PAGE gel. Actin was used as the loading control.

Figure 15. PD98059 doesn't block LPA-induced Cyr61 protein expression. Quiescent
MASMCs were pretreated with PD98059 at the concentrations indicated above for 45 minutes,
then 5M LPA was added in the medium for 3 hours. Cyr61 protein level was determined by
Western blotting with 10% SDS-PAGE gel. The expression of Actin was used as the loading
control.
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Figure 16. SB203580 doesn't block LPA-induced Cyr61 protein expression. Quiescent
MASMCs was pretreated with SB203580 at the concentrations indicated above for 45 minutes,
then 5 M LPA was added in the medium for 3 hours. Cyr61 protein level was determined by
Western blotting with 10% SDS-PAGE gel. The expression of Actin was used as the loading
control.

Figure 17. SP600125 doesn't block LPA-induced Cyr61 protein expression. Quiescent
MASMCs were pretreated with SP600125 for 45 minutes, then 5 M LPA was added in the
medium for 3 hours. Cyr61 protein level was determined by Western blotting with 10%
SDS-PAGE gel. Actin was detected as the loading control.
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1.5 PKD is not involved in LPA-induced cyr61 expression.
One of the earliest responses of many cell types to extracellular stimuli is an
increase in the synthesis of DAG, and protein kinase D (PKD) which is a DAG
regulated protein kinase that plays a role in mediating some of the cellular responses
initiated by DAG-producing receptors [39]. Our group has reported thrombin rapidly
induces PKD phosphorylation [40], angiotensin II induces protein kinase D activation
[41] and PKD2 regulates LPC-induced PC3 cell migration [42]. LPA also induces
phosphorylation of PKD in MASMCs (Figure 13), therefore, we determined whether
PKD is involved in LPA-induced Cyr61 expression. MASMCs were pretreated with
different doses of Resveratrol, a PKD inhibitor, then 5 M LPA was added, as shown
in the figure 18, Resveratrol doesn't block LPA-induced Cyr61 expression, suggesting
PKD is not involved in Cyr61 protein accumulation induced by LPA. Furthermore,
siRNA transfection experiment has been performed to confirm this result. MASMCs
were tranfected with PKD1 and PKD2 siRNA for 48 hours, the cells were starved for
48 h followed by LPA treatment. As shown in figure 19, treatment with neither PKD1
nor PKD2 siRNA blocked the induction of Cyr61 expression by LPA. Taken together,
these results demonstrate that LPA-induced Cyr 61 expression is not mediated by
PKD.
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Figure 18. Resveratrol doesn't block LPA-induced Cyr61 protein expression. Quiescent
MASMCs were pretreated with Resveratrol at the concentrations indicated above for 45 minutes,
then 5 M LPA was added in the medium for 3 hours. Cyr61 protein level was determined by
Western blotting with 10% SDS-PAGE gel. Actin level was used as the loading control.

Figure 19. Transfection of PKD1 and PKD2 siRNA doesn’t block LPA-induced Cyr61
protein expression in MASMCs. MASMCs were transfected with PKD1 and PKD2 siRNA for
48 hours, after being starved for 48 hours, the cells were stimulated with or without LPA, the
expression levesl of PKD1 & PKD2 were determined with specific antibodies to monitor the
knockdown level of Cyr61. Cyr61 protein level was determined by western blotting with 10%
SDS-PAGE gel.
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1.6 LPA-induced Cyr61 expression is not mediated by PI3Ks.
Phosphoinositide 3-kinases (PI 3-kinases or PI3Ks) include a family of enzymes
involved in cellular functions such as cell growth, differentiation, motility,
proliferation, survival and intracellular trafficking. The PI3K pathway is implicated in
human diseases including diabetes and cancer [43] . Our previous results showed LPA
significantly induced the phosphorylation of Akt (Figure 13), which is downstream of
PI3Ks. To determine whether PI3Ks pathway is involved LPA induction of Cyr61, we
pretreated MSMCs with various concentrations of PI3Ks inhibitor LY294002 and
Wortmanin for 45 minutes, then incubated the cells with 5 M LPA for 3 hours, as
shown in Figures 20 and 21, Both inhibitors didn't have any effect on LPA-induced
Cyr61 protein expression, implying that PI3Ks does not play a role in Cyr61
production induced by LPA.
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Figure 20. LY294002 doesn't block LPA-induced Cyr61 protein expression. Quiescent
MASMCs were pretreated with LY294002 at the concentrations indicated above for 45 minutes,
then 5 M LPA was added in the medium for 3 hours. Cyr61 protein level was determined by
western blotting with 10% SDS-PAGE gel. Actin was detected as the loading control.

Figure 21. Wortmannin doesn't block LPA-induced Cyr61 protein expression. Quiescent
MASMCs was pretreated with Wortmannin at the concentrations indicated above for 45 minutes,
then 5 M LPA was added in the medium for 3 hours. Cyr61 protein level was determined by
Western blotting with 10% SDS-PAGE gel. Actin was detected as the loading control.
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1.7 LPA-Induced Cyr61 Expression is mediated by PKC
We have excluded the possibility that MAPKs, PKD and PI3Ks were involved in
LPA induction of Cyr61, so next we want to determine which kinase(s) mediates
LPA-induced Cyr61 expression. Protein kinase C (PKC) is a family of enzymes,
which play important roles in many signal transduction pathways by mediating the
functions of many proteins through the phosphorylation of hydroxyl groups of serine
and threonine amino acid resides. Our group has reported histamine induces Egr-1
expression in human aortic endothelial cells via the H1 receptor-mediated protein
kinase Cdelta-dependent ERK activation pathway [44]. To investigate whether PKC
mediates LPA-induced Cyr61 protein expression, we pretreated MSMCs with
indicated concentrations of pan PKC inhibitor GF109203X and GO6983 for 45
minutes, then incubated the cells with 5 M LPA for 3 hours, as shown in Figures 22
and 23, Both of those inhibitors dose-dependently block LPA-induced Cyr61 protein
expression, strongly supporting that PKC mediates LPA induced Cyr61 expression.
The PKC family consists at least ten isozymes [45], and they are divided into three
subfamilies, conventional, novel, and atypical based on their second messenger
requirements. It is unknown which PKC subtype is involved in LPA-induced Cyr61
expression; our result shows LPA highly induces the phosphorylation of
PKCFigure 24
To examine whether PKCmediates LPA-induced Cyr61 expression, we
pretreated MSMCs with various concentrations of PKC inhibitor, Rottlerin and
PKCinhibitor,GO6976 for 45 minutes, then incubated cells were treated with 5
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M LPA for 3 hours, as shown in figure 25, Rottlerin markedly blocked LPA-induced
Cyr61

protein

expression

in

a

dose-dependent

manner.

In

contrast,

PKCinhibitor,GO6976 had no effect on LPA-induced Cyr61 protein expression
Figure 26. These data strongly support a key role of PKC in mediating
LPA-induced Cyr61 protein expression.
To further confirm the above results, we performed small siRNA knockdown
exprements, MASMCs were tranfected with PKC siRNA for 48 hours; then the cells
were starved for 48 h followed by treatment of LPA. As shown in figure 27,
PKCsiRNA completely blocks PKC expression and LPA-induced Cyr61
expression. In addition, we infected MASMCs with PKCdominant-negative
adenovirus and wildtype adenovirus, we observed that infection of PKCdominant
negative adenovirus blocked LPA-induced Cyr61 expression in MASMCs. As a
positive

control,

LPA

highly

induces

Cyr61

expression

after

wildtype

PKCadenovirus infection in MASMCs (Figure 28). All of those data support the
conclusion that PKC mediates LPA-induced Cyr61 protein expression.
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Figure 22. PKC inhibitor GF109203X blocks LPA-induced Cyr61 protein expression.
Quiescent MASMCs were pretreated with GF109203X at the concentrations indicated above for
45 minutes, then 5M LPA was added in the medium for 3 hours. Cyr61 protein level was
determined by western blotting with 10% SDS-PAGE gel. Actin was detected as the loading
control.

Figure 23. Go6983 blocks LPA-induced Cyr61 protein expression. Quiescent MASMCs was
pretreated with GO6983 at the concentrations indicated above for 45 minutes, then 5 M LPA was
added in the medium for 3 hours. Cyr61 protein level was determined by Western blotting with
10% SDS-PAGE gel. Actin was detected as the loading control.
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Figure 24. LPA induces phosphorylation of PKCbut not other PKC subtypes in MASMCs.
5 M LPA was added to quiescent MASMC at the time points indicated above. Phosphorylation of
PKC subtypes were determined by Western blotting with 10% SDS PAGE gel.
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Figure 25. Rottlerin blocks LPA-induced Cyr61 protein expression. Quiescent MASMCs were
pretreated with Rottlerin at the concentrations indicated above for 45 minutes, then 5 M LPA was
added in the medium for 3 hours. Cyr61 protein level was determined by Western blotting with
10% SDS-PAGE gel. Actin was detected as the loading control.

Figure 26. GO6976 doesn't block LPA-induced Cyr61 protein expression. Quiescent
MASMCs were pretreated with G06976 at the concentrations indicated above for 45 minutes, then
5 M LPA was added in the medium for 3 hours. Cyr61 protein level was determined by Western
blotting with 10% SDS-PAGE gel. Actin was detected as the loading control.
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Figure 27. Transfection of PKC siRNA blocks LPA-induced Cyr61 protein expression in
MASMCs. MASMCs were transfected with PKC siRNA for 48 hours, after being starved for 48
hours, the cells were stimulated with or without LPA. Cyr61 protein level was determined by
Western blotting with 10% SDS-PAGE gel. Actin was detected as the loading control, PKCwas
detected with the specific antibody to show the knockdown level.
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Figure 28. Infection of PKC dominant negative adenovirus blocks LPA-induced Cyr61
protein expression in MASMCs. MASMCs were infected with type and dominant negative
PKC viruses for 12 hours, after being starved for 48 hours, the cells were stimulated with or
without LPA. Cyr61 protein level was determined by Western blotting with 10% SDS-PAGE gel.
PKCwas detected with the specific antibody to show the efficiency of infection.
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2. The dynamic localization of LPA-induced Cyr61
protein in MASMCs.

2.1 LPA markedly induced Cyr61 protein intracellularly and the
induced Cry61 is deposited in the extracellular matrix.
Cyr61 is an extracellular matrix protein, it exerts its function mostly in the
extracellular matrix, and the above data showed that LPA markedly induces Cyr61
protein expression. To investigate the localization of LPA-induced Cyr61 protein, we
stimulated quiescent MASMCs with 5 M LPA for various time periods, both cell
lysates and extracellular matrix were collected and detected with a specific Cyr61
antibody, as shown in figure 29, after 20 min stimulation, LPA rapidly induces Cyr61
protein expression intracellularly, however, the increased Cyr61 protein level can only
be detected in the extracellular matrix after LPA stimulation for 1 hour. All of those
data demonstrate that LPA rapidly induces Cyr61 protein expression intracellularly
and the induced Cyr61 translocates outside the plasma membrane and is deposited in
the extracellular matrix.
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Figure 29. LPA highly induces Cyr61 protein expression intracellularly and LPA-induced
Cyr61 protein is deposited in the extracellular matrix. MASMCs were detached from the
dishes with 1mM EDTA and lysed in the lysis buffer, and ECM remaining on the culture dishes
was extracted in Laemmli sample buffer. Cyr61 protein level was determined by Western blotting
with 10% SDS PAGE gel. Actin was used as an internal control.
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2.2 The dynamic localization of LPA-induced Cyr61 protein in
MSMCs.
Although the above data gave us a brief view the localization of LPA-induced
Cyr61 protein, it is still unclear that through which subcellular compartments,
LPA-induced

Cyr61

protein

is

translocated

to

the

extracellular

matrix.

Immunofluorescence analysis has been performed to further explore this question.
Quiescent MASMCs were stimulated with LPA for various time periods as shown in
figure 30, after paraformaldehyde fixation, the cells were treated with 0.3% triton
X-100 for permeabilization of the plasma membrane and then the cells were
immunostained with the specific antibodies against Cyr61, DAPI ( a specific nuclear
marker ) and Adaptin ( a specific Golgi apparatus marker ). The results showed that
intracellular Cyr61 protein was highly induced after 1 hour LPA treatment, moreover,
the image of LPA-induced Cyr61 protein and Golgi apparatus marker adaptin merged
together perfectly, indicating that after Cyr61 mRNA being translated into Cyr61
protein, these proteins immediately accumulate in the Golgi apparatus for further
processing prior to the secretion into the extracellular matrix. We also observed that
the intracellular Cyr61 protein induced by LPA decreased after 1 hour, whereas the
extracellular Cyr61 increased, strongly supporting that LPA-induced Cyr61 proteins
first accumulated in the Golgi apparatus and then were secreted to the extracellular
matrix. We also used another approach to directly observe the LPA-induced Cyr61
deposition on the extracellular matrix. We treated the cells without Triton X100 and
then immunostained the cells with Cyr61 antibody. As shown in figure 31, Cyr61
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protein in the extracellular matrix was highly induced by LPA after 3 hr stimulation.

- 47 -

Figure 30. Dynamic localization of Cyr61 protein induced by LPA. MASMCs were cultured
on microscope cover glasses, after 48 hours starvation, cells were stimulated with LPA for various
time periods indicated above; then cells were immunostained with the Cyr61 antibody, DAPI
(nuclear marker) antibody and Adaptin (Golgi Apparatus marker) antibody after triton X-100
treatment.
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Figure 31. Localization of LPA-induced Cyr61 protein in the extracellular matrix. MASMCs
were cultured on microscope cover glasses, after 48 hours starvation, cells were stimulated with
LPA for 3 hours, and then fixed with paraformaldehyde solution followed by immunostaining
with the specific Cyr61 antibody, DAPI (nuclear marker) antibody, Adaptin (Golgi Apparatus
marker) antibody without triton X-100 treatment.
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3. Cyr61 mediates LPA-induced MASMC migration.

3.1 Cyr61 is involved in LPA-induced MASMC migration.
As shown above, our data demonstrate that LPA markedly induces Cyr61
expression and secretion into extracellular matrix. High concentrations of LPA and
Cyr61 have been found in atherosclerotic lesions [9][46]. We hypothesize that
LPA-induced Cyr61 mediates LPA signaling leading to cell migration. To date,
whether Cyr61 contributes to LPA-induced cell migration is unknown.
To determine whether LPA-induced MASMC migration is mediated by Cyr61,
we applied an antibody neutralization approach. We pretreated MASMC with the
specific Cyr61 antibody for 45 minutes and stimulated the cells with LPA, the cells
were then subjected to the migration assay, and we observed that LPA-induced cell
migration was reduced about 80% after the Cry61 antibody treatment, suggesting
Cyr61 mediates LPA-induced MASMC migration induced by LPA (Figure 29).
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Figure 32. Cyr61 is involved in LPA-induced MASMC migration. MASMCs were pretreated
with or without Cyr61 antibody for 45 minutes and then subjected to a migration assay in response
to 5 M LPA.
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3.2 LPA1 receptor and PKC mediate LPA-induced MASMC
migration.
As demonstrated above, LPA-induced Cyr61 expression was through LPA1
receptor and mediated by PKC, and Cyr61 was involved in LPA-induced MASMC
migration. These data implied that LPA1 receptor and PKC may also play roles in the
MASMC migration. To determine which LPA receptor mediates cell migration, we
performed cell migration assay using wildtype, LPA1-/-, LPA2-/- MAMSCs stimulated
with LPA. We found that genetic deletion of LPA1, but not LPA2 blocked
LPA-induced cell migration, indicating that LPA1 but not LPA2 mediates LPA-induced
MASMC migration (Figure.30). We next determined whether PKC mediated
LPA-induced MASMC migration, quiescent MASMCs were stimulated with 5 M
LPA after being pretreated with pan-PKC inhibitor GF109203X for 45 minutes, and
then subjected to the cell migration assay. As shown in figure 31, PKC specific
inhibitor GF109203X completely blocked LPA-induced MASMC migration, these
data indicate that LPA1- and PKC-mediated LPA-induced Cyr61 protein expression is
a key event in LPA-induced MASMC migration.
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Figure 33. LPA induces the MASMC migration, and the migration is mediated by LPA1
receptor, but not LPA2 receptor. Quiescent wildtype, LPA1-/-, LPA2-/- MASMCs were stimulated
with 5 M LPA, and then subjected to a migration assay.
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Figure 34. The effect of GF109203X on LPA-induced MASMC migration. MASMCs were
pretreated either with or without PKC inhibitor GF109203X for 45 minutes and then subjected to
a migration assay in response to 5 M LPA.
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DISCUSSION

One of the important risk factors in the pathogenesis of atherosclerosis is
oxidized low density lipoprotein (LDL). LPA is one of the most bioactive lipid
components in oxidized LDL. LPA plays a very important role in initiating platelet
activation and stimulating endothelial cell stress-fiber and gap formation. It has been
found that LPA is the most important platelet-activating lipid of atherosclerotic
plaques and also highly accumulated in lipid-rich core in the atherosclerotic lesion.
Our group has reported that LPA increased TF mRNA, TF protein, and TF pathway
activity via transcription factor, Egr-1 [35]. In addition, LPA also prominently induces
the secretion of IL-6 and monocyte chemoattractant protein (MCP)-1 from human
aortic SMCs (HASMCs) [47]. These data indicated the important roles of LPA in the
initiation and progression of atherosclerosis.
Cyr61 has been shown to be highly expressed in human atherosclerotic plaques,
correlating with the degree of stenosis and plaque histopathology [46]. The
upregulation of Cyr61 in VSMCs was first identified in the screening for genes that
are differentially expressed in response to Ang II stimulation in vascular smooth
muscle cells [48]. Cyr61 is an extracellular matrix-associated angiogenic inducer that
promotes cell adhesion, migration, and proliferation. Aberrant expression of Cyr61 is
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associated with wound healing, and vascular diseases such as atherosclerosis [49].
Whether Cyr61 plays a role in LPA-induced cell migration is currently unknown. In
this study, we determined the relationship between LPA and Cyr61 in VSMCs, and
their roles in vascular function. Our Western blot analysis and Northern blot analysis
demonstrate that LPA markedly induces Cyr61 protein and mRNA expression. The
induction is LPA dose- and time-dependent in MASMCs.
LPA is well known as an important signaling molecule to produce many cellular
responses.

These

responses

were

explained

by

both

non-receptor

and

receptor-mediated mechanisms. LPA is a direct agonist of the nuclear transcription
factor PPARgamma [50]. Here our results showed PPARgamma was not involved in
LPA-induced Cyr61 expression. Currently, there are at least 5 LPA receptors that
couple with several types of G proteins, Gs, Gi/o, Gq, and G12/13. By activation of
these G proteins, LPA induces cell proliferation, cell migration, MAPK activation,
PLC activation, PKC activation, Ca2+ mobilization, Akt activation, and Rho
activation [17][51][52][53]. It was reported that LPA stimulates prostaglandin E2
production in cultured stromal endometrial cells through LPA1 [54]. In vascular
systems, our RT-RCR data clearly showed that LPA1, LPA2 and LPA4 receptors were
highly expressed. Our group has published the data showing that LPA induces IL-6
secretion from aortic smooth muscle cells via an LPA1-regulated pathway [49], and
LPA1 receptor also mediates prostate cancer PC3 cell migration [55]. In this study,
our Western blot analysis demonstrated that LPA-induced Cyr61 expression was
mediated by LPA1 receptor, but not LPA2 receptor. Up to date, the signaling pathway
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involved in LPA induced-Cyr61 expression was unknown. LPA was shown to activate
MAPKs, Akt and PKD, which are frequently involved in LPA-induced G-protein
coupled signaling pathways. It has been found that LPA stimulates gastric cancer cell
proliferation via Erk dependent upregulation of sphingosine kinase 1 transcription
[56]. Chiu, TT et al., reported in 2007 that protein kinase D2 mediates
lysophosphatidic acid-induced interleukin 8 production in nontransformed human
colonic epithelial cells through NF-kappaB [57]. Singla, A et al. reported in 2009 that
LPA-mediated stimulation of Cl(-)/OH(-) exchange activity was depending on
activation of phosphatidylinositol 3-kinase/Akt signaling pathway. In this study, our
Western blot analysis data showed that none of those kinases were involved in
LPA-induced Cyr61 expression, indicating that an unveiled specific signaling
pathway leads to LPA-induced Cyr61 expression.
It was reported that LPA-induced NF-kappaB activation and cytokine production
were mediated by PKCs but not by JNK, p38 or Erk MAP kinase. Our previous data
also showed that histamine activates the phosphorylation of PKC and that PKC
mediates histamine-induced Egr-1 expression in RASMCs and human endothelial
cells [44]. To investigate whether PKC pathway mediated LPA-induced Cyr61
expression, we used PKC specific inhibitors, the dominant negative virus constructs
and

siRNA

to

block

PKCexpressionOur

the

Western

functions
blotting

of

PKCand

results

clearly

to

knockdown

demonstrated

of
that

LPA-induced Cry61 expression was blocked by each of these approaches, strongly
supporting our conclusion that PKCmediated LPA-induced Cry61 expression.
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Another interesting finding in this study is the dynamic localization of LPA
induced-Cyr61 protein. Cyr61 is a matricellular protein. It is important to know the
transportation of Cyr61 protein after Cyr61 mRNA is translated. Our Western blotting
data demonstrated that the intracellular Cyr61 protein was highly induced by LPA
stimulation within 20 minutes, and then via Golgi, Cyr61 was secreted into
extracellular matrix. The peak time difference in Cyr61 protein accumulation in
intracellular compartment and extracellular matrix suggests a dynamic transportation
of LPA-induced Cry61 protein from the intracellular compartments to the ECM. Our
immunocytochemistry results confirmed the Western blot results.
Atherosclerosis is a chronic arterial disease where vascular smooth muscle cells
(VSMCs), inflammatory cells, lipids, cholesterol and cellular products like cytockines
work together to produce a fibro-fatty plaque and initiate neointima formation [58]. It
has been shown that the neointimal SMCs are derived from the media after balloon
endothelial denudation or cholesterol-induced injury [59]. The importance of smooth
muscle cell migration in neointima formation of atherosclerosis is well appreciated.
Studies have been done to support the role of LPA in the smooth muscle cell
migration (citation). Zhou et al in 2009 reported LPA induced vascular smooth muscle
migration via p38 mitogen-activated protein kinase pathway activation [60]. Lin BR
et al. in 2007 reported that Cyr61 enhanced transendothelial cell migration by
concomitantly up-regulating chemokine receptor 1 and 2 [61]. It was also reported
that recombinant Cyr61 protein induces SMC migration in a dose-dependent manner
[62]. But it was unknown whether Cyr61 played a role in LPA induced MASMC
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migration. In this study, we found that Cyr61 neutralizing antibody significantly
blocked LPA-induced MASMCs migration, indicating Cyr61 mediates LPA-induced
MASMC migration. In addition, our cell migration analysis data clearly demonstrated
that LPA-induced MASMC migration is mediated by LPA1 and PKC kinase. LPA1
and PKC are responsible for LPA-induced Cyr61 expression.
Taken together, the above results demonstrate that LPA, via LPA1 receptor,
activates a specific signaling pathway leading to PKC activation, which in turn,
mediates LPA-induced Cyr61 protein in MASMCs. LPA-induced Cyr61 proteins first
accumulated in the Golgi apparatus then were secreted into extracellular matrix. Our
data further show that LPA-induced Cyr61 is responsible for LPA-induced SMC
migration, which may contribute to the development of atherosclerosis. The
identification of the specific LPA receptor and PKCdelta, especially the novel
LPA/Cyr61 pathway in controlling smooth muscle cell migration, provides new
insight into mechanisms underlying the pathogenesis of atherosclerosis.
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Figure 36. A diagram showing the signaling pathway by which LPA induces Cyr61 and
MASMC migration.
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